ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis

Company Overview

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders and rare diseases. The company is headquartered in San Diego, California, and serves patients and healthcare providers primarily in the United States.

ACADIA’s commercial products include NUPLAZID (pimavanserin), an atypical antipsychotic approved in the United States for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company also markets DAYBUE (trofinetide), a therapy for Rett syndrome in adults and children aged two years and older. Trofinetide was developed by Neuren Pharmaceuticals, with ACADIA holding commercialization rights in North America.

Founded in 1993, ACADIA has historically concentrated on neurological and neuropsychiatric conditions with significant unmet medical needs. The company continues to support its marketed products while advancing a pipeline of potential treatments for central nervous system and rare neurological disorders. Steve Davis serves as ACADIA’s president and chief executive officer.

Key Stats

• Today's Range: $18.87 to $19.76
• 50-Day Range: $18.62 to $30.57
• 52-Week Range: $18.39 to $30.96
• Volume: 1.67 million shs
• Average Volume: 2.55 million shs
• Market Capitalization: $3.29 billion
• P/E Ratio: 8.61
• Dividend Yield: N/A
• Price Target: $31.34
• Consensus Rating: Moderate Buy

ACADIA Pharmaceuticals Stock Analysis - MarketRank™

ACADIA Pharmaceuticals scored higher than 95% of companies evaluated by MarketBeat, and ranked 11th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.72, and is based on no strong buy ratings, 13 buy ratings, 5 hold ratings, and no sell ratings.

Upside Potential

ACADIA Pharmaceuticals has a consensus price target of $31.34, representing about 63.9% upside from its current price of $19.12.

Amount of Analyst Coverage

ACADIA Pharmaceuticals has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 53.13%

Earnings Growth

Earnings for ACADIA Pharmaceuticals are expected to grow by 53.13% in the coming year, from $0.64 to $0.98 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ACADIA Pharmaceuticals is 8.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 35.61.

Price to Earnings Ratio vs. Sector

The P/E ratio of ACADIA Pharmaceuticals is 8.61, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 200.16.

Price to Book Value per Share Ratio

ACADIA Pharmaceuticals has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.51% of the float of ACADIA Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

ACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 2.93, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ACADIA Pharmaceuticals has recently decreased by 14.39%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ACADIA Pharmaceuticals does not currently pay a dividend.

Dividend Growth

ACADIA Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.08

News Sentiment

ACADIA Pharmaceuticals has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for ACADIA Pharmaceuticals this week, compared to 8 articles on an average week.

Search Interest

Only 3 people have searched for ACAD on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,019,894.00 in company stock.

Percentage Held by Insiders

26.20% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/17/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ACAD
• CIK: 1070494
• Web: www.acadia.com
• Phone: (858) 558-2871
• Fax: 858-558-2872
• Employees: 798
• Year Founded: 1993

Price Target and Rating

• Average Price Target for ACADIA Pharmaceuticals: $31.34
• High Price Target: $37.00
• Low Price Target: $14.50
• Potential Upside/Downside: +63.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.72
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.22
• Trailing P/E Ratio: 8.61
• Forward P/E Ratio: 29.88
• P/E Growth: N/A
• Net Income: $391 million
• Net Margins: 33.42%
• Pretax Margin: 10.66%
• Return on Equity: 9.03%
• Return on Assets: 6.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.39
• Quick Ratio: 3.30

Sales & Book Value

• Annual Sales: $1.07 billion
• Price / Sales: 3.07
• Cash Flow: $0.86 per share
• Price / Cash Flow: 22.22
• Book Value: $7.25 per share
• Price / Book: 2.64

Miscellaneous

• Outstanding Shares: 172,310,000
• Free Float: 127,162,000
• Market Cap: $3.29 billion
• Optionable: Optionable
• Beta: 0.88